Onconova Therapeutics
ONTX
$1.00
Share price
-0.47%
Change (1 day)
42.19%
Change (1 year)
Categories
P/S ratio for Onconova Therapeutics (ONTX)
P/S ratio as of April 2024 (TTM): 92.5
According to Onconova Therapeutics's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 92.4986. At the end of 2023 the company had a P/S ratio of 69.3.
P/S ratio history for Onconova Therapeutics from 2013 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 69.3 | 15.9% |
| 2022 | 59.8 | -74.64% |
| 2021 | 236 | -36.8% |
| 2020 | 373 | 1812.12% |
| 2019 | 19.5 | 100.05% |
| 2018 | 9.75 | -52.51% |
| 2017 | 20.5 | 641.98% |
| 2016 | 2.77 | 30.1% |
| 2015 | 2.13 | -97.62% |
| 2014 | 89.3 | 72.14% |
| 2013 | 51.9 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Baxter BAX | 1.35 | -98.54% | 🇺🇸 USA |
 Spectrum Pharmaceuticals
SPPI | 8.22 | -91.12% | 🇺🇸 USA |
 CTI BioPharma
CTIC | 15.8 | -82.90% | 🇺🇸 USA |
 Cleveland BioLabs
CBLI | N/A | N/A | 🇺🇸 USA |
 Array Technologies ARRY | 1.06 | -98.86% | 🇺🇸 USA |